SandboxAB: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 30: | Line 30: | ||
{| | {| | ||
|- | |- | ||
| valign= | | valign=top | | ||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: center; width:25em" cellpadding="0" cellspacing="0"; | {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: center; width:25em" cellpadding="0" cellspacing="0"; | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B| Fungal cystitis in the non-neutropenic patient}}'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B| Fungal cystitis in the non-neutropenic patient}}'' | ||
Line 42: | Line 42: | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amphotericin B ]] 0.3 - 0.6 mg/kg IV once daily×1-7 days''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amphotericin B ]] 0.3 - 0.6 mg/kg IV once daily×1-7 days''''' | ||
|} | |} |
Revision as of 05:42, 17 January 2014
‡Avoid if resistance prevalence is known to exceed 20% or if used for UTI in previous 3 months. ♦Pivmecillinam is available in some European countries, not licensed in US.
|